Business
Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science
Company Announces Appointment of Jeffery Lichtenhan, Ph.D., to Lead Efforts in Hearing Diagnostics and Measurement; Joins Frequency from Washington
About this update from Korro Bio, Inc.
[{"type":"text","content":"\nCompany Announces Appointment of Jeffery Lichtenhan, Ph.D., to Lead Efforts in Hearing Diagnostics and Measurement; Joins Frequency from Washington University Medical School in St. Louis\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement.\n\nDr. Lichtenhan, an auditory neuroscientist, will help to advance the Company’s hearing clinical development programs, including its lead program, FX-322, which aims to regenerate sensory hair cells to potentially restore hearing for individuals with sensorineural hearing loss (SNHL). He joins Frequency from the Washington University School of Medicine in St. Louis, where he was Assistant Professor of Otolaryngology and Audiology and Communication Sciences. Dr. Lichtenhan’s laboratory has aimed to develop novel, clinically relevant measures of auditory dysfunction and he has published more than 25 peer-reviewed studies on this topic.\n\nAt Frequency, Dr. Lichtenhan will develop strategies to turn laboratory and clinical observations into new, increasingly sensitive diagnostic methodologies to support development of new therapeutics for acquired sensorineural hearing loss, the most common form of hearing loss.\n\n“We are excited to continue welcoming world-class experts to Frequency and extending our field-leading expertise in hearing science. Jeff’s focus on diagnostics and inner ear dysfunction will support our advancement of the FX-322 hearing restoration program into new clinical studies, and more broadly build upon our novel regenerative medicine platform,” said David L. Lucchino, Frequency’s President and Chief Executive Officer.\n\nDr. Lichtenhan’s appointment further broadens the Company’s internal audiology and hearing science expertise, as Frequency continues to build out its hearing research and development efforts, while working to define specific patient populations where its lead treatment candidate, FX-322, may have the greatest impact. In February, Frequency announced the appointment of Kevin Franck, Ph.D., who j...